Purpose: Pediatric hematology/oncology patients frequently use the emergency department (ED) for prompt care during potentially life-threatening events, such as sepsis and bleeding. One challenge of these visits is the unavailability of appropriate patient-specific medical information. Lack of information may result in ineffective ED visits for these patients with complex conditions.
Methods: A cross-sectional survey to determine ways to improve the care of pediatric hematology/oncology patients in the ED setting was conducted among parents at two affiliated pediatric hematology/oncology clinics. ED physicians in the catchment area of the clinic completed a separate survey.
Results: All physicians surveyed were confident in caring for pediatric patients in the ED; however, fewer were confident in caring for pediatric hematology/oncology patients. Physicians and parents reported that the patient's written medical history (physicians, 30%; parents, 33%), medication list (physicians, 28%; parents, 24%), on-call pediatric hematologist/oncologist contact information (physicians, 34%; parents, 31%), and needle size and gauge to access the patient's port (physicians, 8%; parents, 12%) would be valuable information to have when presenting to the ED.
Conclusion: Parents were satisfied with ED care, but both physician and parent respondents thought additional information would be valuable to have available at the visit to help facilitate effective care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JOP.2013.001114 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying Adolescent and Young Adults' Preferences for Oncology Symptom Management Clinical Trial Participation.
Cancer Nurs
January 2025
Author Affiliations: Department of Health and Clinical Sciences, University of Michigan School of Nursing (Dr Knoerl and Mss Smener and Grandinetti); Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical School (Drs Fecher, Henry, Karimi, Pettit, and Schuetze); Pediatric Hematology/Oncology, C.S. Mott Children's Hospital (Dr Walling); and School of Social Work, University of Michigan (Dr Zhang), Ann Arbor; and College of Nursing, The University of Tennessee, Knoxville (Dr Barton).
Background: Most studies to date exploring facilitators and barriers to adolescent and young adults' (AYAs') participation in clinical trials have been focused on external factors to AYAs' participation or recruitment strategies.
Objective: The purpose of this mixed-methods study was to determine AYA cancer survivors' preferences for oncology symptom management clinical trial participation.
Methods: Semistructured interviews and conjoint analysis were conducted to clarify potential attributes (eg, characteristics) and levels (eg, value of the characteristic) that may be important to AYA cancer survivors when considering clinical trial participation (n = 19).
Computerized assessment of neuropsychological functioning in pediatric brain tumor patients.
J Neurooncol
January 2025
Department of Neurosurgery, MacKay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd, Taipei, 10449, Taiwan.
Purpose: Advances in multidisciplinary treatment of childhood brain tumors have significantly prolonged survival and reduced treatment-related complications. This makes the accessibility of digital neurocognitive assessment an important issue in the post-pandemic era.
Methods: Twenty pediatric brain tumor patients were recruited between August 2023 and August 2024, and a total of eight standardized Cambridge Neuropsychological Test Automated Battery (CANTAB) tests targeting executive function, memory, and attention were applied on a digital system.
Targeting the Menin-KMT2A interaction in leukemia: Lessons learned and future directions.
Int J Cancer
January 2025
DGHO, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. working group, Clinical and Translational Epigenetics, Berlin, Germany.
Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A-locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N-terminal part of KMT2A is fused to a variety of translocation partners. The most frequently found fusion partners of KMT2A in acute leukemia are the C-terminal parts of AFF1, MLLT3, MLLT1 and MLLT10.
View Article and Find Full Text PDFMulti-Step Assembly of an RNA-Liposome Nanoparticle Formulation Revealed by Real-Time, Single-Particle Quantitative Imaging.
Adv Sci (Weinh)
January 2025
Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of Texas at Austin, Austin, TX, 78712, USA.
Self-assembly plays a critical role in nanoparticle-based applications. However, it remains challenging to monitor the self-assembly of multi-component nanomaterials at a single-particle level, in real-time, with high throughput, and in a model-independent manner. Here, multi-color fluorescence microscopy is applied to track the assembly of both liposomes and mRNA simultaneously in clinical mRNA-based cancer immunotherapy.
View Article and Find Full Text PDFMolecular Characteristics of a Fusion Gliosarcoma: A Case Report.
Int J Surg Pathol
January 2025
Department of Pathology, Rambam Health Care Campus, Haifa, Israel.
The combination of ependymoma and gliosarcoma elements in the same tumor is extremely rare, and the molecular characteristics of these entities are not clear. Here, we present a rare aggressive brain tumor in a 12-year-old boy harboring a gene fusion, a characteristic feature of supratentorial ependymomas. On the other hand, the histopathological, molecular, and methylation profiles were compatible with a diagnosis of a mesenchymal type, IDH wild-type glioblastoma multiforme (GBM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!